Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

Oncotarget

Volumn 7, Issue 47, 2016, Pages 76534-76550

  Murai, Junko ^a   Feng, Ying ^b   Yu, Guoying K ^b   Ru, Yuanbin ^b   Tang, Sai Wen ^a,c   Shen, Yuqiao ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ATR; BRCA, homologous recombination; PARP inhibitor; PARP trapping

Indexed keywords

ATR PROTEIN; OLAPARIB; TALAZOPARIB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; ATM PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEAR PROTEIN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; SLFN11 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DRUG PENETRATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE; GENE EXPRESSION; GENE INACTIVATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; S PHASE CELL CYCLE CHECKPOINT; SLFN11 GENE; SMALL CELL LUNG CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE SILENCING; GENETICS; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE SILENCING; HOMOLOGOUS RECOMBINATION; HUMANS; MICE; NUCLEAR PROTEINS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84998827879     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12266     Document Type: Article

References (57)

1. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10: 293-301. doi: 10.1038/nrc2812.
2. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013; 19: 5003-15. doi: 10.1158/1078-0432.CCR-13-1391.
3. Benjamin RC, Gill DM. ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage in DNA. J Biol Chem. 1980; 255: 10493-501. doi:.
4. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose) n participates in DNA excision repair. Nature. 1980; 283: 593-6. doi:.
5. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434: 913-7. doi: 10.1038/nature03443.
6. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434: 917-21. doi: 10.1038/nature03445.
7. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014; 13: 433-43. doi: 10.1158/1535-7163.MCT-13-0803.
8. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72: 5588-99. doi: 10.1158/0008-5472.CAN-12-2753.
9. Murai J, Pommier Y. (2015). Classification of PARP inhibitors based on PAPR trapping and catalytic inhibition, and rationale for combination with topoisomerase I inhibitors and alkylating agents. In: Sharma NJCaRA, ed. PARP inhibitors for Cancer Therapy. (Switzerland: Springer International Publishing ).
10. Nam EA, Cortez D. ATR signalling: more than meeting at the fork. Biochem J. 2011; 436: 527-36. doi: 10.1042/BJ20102162.
11. Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014; 16: 2-9. doi: 10.1038/ncb2897.
12. Friedel AM, Pike BL, Gasser SM. ATR/Mec1: coordinating fork stability and repair. Curr Opin Cell Biol. 2009; 21: 237-44. doi: 10.1016/j.ceb.2009.01.017.
13. Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y. The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and-DNA Fiber Analyses. Mol Cell Biol. 2007; 27: 5806-18. doi:.
14. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, Friend SH. Overexpression of a kinaseinactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 1998; 17: 159-69. doi:.
15. Claus Storgaard Sørensen HB, Viola Nähse-Kumpf and Randi G. Syljuåsen (2011). Faithful DNA Replication Requires Regulation of CDK Activity by Checkpoint Kinases. In: Seligmann DH, ed.: InTech.
16. Josse R, Martin SE, Guha R, Ormanoglu P, Pfister TD, Reaper PM, Barnes CS, Jones J, Charlton P, Pollard JR, Morris J, Doroshow JH, Pommier Y. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014; 74: 6968-79. doi: 10.1158/0008-5472.CAN-13-3369.
17. Karnitz LM, Zou L. Molecular Pathways: Targeting ATR in Cancer Therapy. Clin Cancer Res. 2015; 21: 4780-5. doi: 10.1158/1078-0432.CCR-15-0479.
18. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6: 813-23. doi: 10.1038/nrc1951.
19. Holbeck SL, Collins JM, Doroshow JH. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther. 2010; 9: 1451-60. doi: 10.1158/1535-7163.MCT-10-0106.
20. Reinhold WC, Sunshine M, Varma S, Doroshow JH, Pommier Y. Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clin Cancer Res. 2015; 21: 3841-52. doi: 10.1158/1078-0432. CCR-15-0335.
21. Zeeberg BR, Reinhold W, Snajder R, Thallinger GG, Weinstein JN, Kohn KW, Pommier Y. Functional categories associated with clusters of genes that are coexpressed across the NCI-60 cancer cell lines. PLoS One. 2012; 7: e30317. doi: 10.1371/journal.pone.0030317.
22. Sousa FG, Matuo R, Tang SW, Rajapakse VN, Luna A, Sander C, Varma S, Simon PH, Doroshow JH, Reinhold WC, Pommier Y. Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair (Amst). 2015; 28: 107-15. doi: 10.1016/j.dnarep.2015.01.011.
23. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, Doroshow JH, Pommier Y. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A. 2012; 109: 15030-5. doi: 1205943109 [pii] 10.1073/pnas.1205943109.
24. Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, Moran S, Heyn H, Sebio A, Barnadas A, Pommier Y, Esteller M. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget. 2016; 7: 3084-97. doi: 10.18632/oncotarget.6413.
25. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483: 603-7. doi: 10.1038/nature11003.
26. Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clin Cancer Res. 2015; 21: 4184-93. doi: 1078-0432.CCR-14-2112 [pii] 10.1158/1078-0432.CCR-14-2112.
27. Deng Y, Cai Y, Huang Y, Yang Z, Bai Y, Liu Y, Deng X, Wang J. High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment. BMC Cancer. 2015; 15: 833. doi: 10.1186/s12885-015-1840-6 10.1186/s12885-015-1840-6 [pii].
28. Mu Y, Lou J, Srivastava M, Zhao B, Feng XH, Liu T, Chen J, Huang J. SLFN11 inhibits checkpoint maintenance and homologous recombination repair. EMBO Rep. 2016; 17: 94-109. doi: 10.15252/embr.201540964.
29. Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier YG. Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther. 2014; 349: 408-16. doi: 10.1124/jpet.113.210146.
30. O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol. 2014; 4: 42. doi: 10.3389/fonc.2014.00042.
31. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G. MGMT testing the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014; 10: 372-85. doi: 10.1038/nrneurol.2014.100.
32. Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012; 5: 102-14. doi:.
33. Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res. 2014; 20: 540-7. doi: 10.1158/1078-0432.CCR-13-0225.
34. Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013; 19: 1381-8. doi: 10.1038/nm.3369.
35. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, Xu X, Deng CX, Finkel T, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010; 141: 243-54. doi: S0092-8674(10)00285-0 [pii] 10.1016/j.cell.2010.03.012.
36. Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013; 3: 68-81. doi: 10.1158/2159-8290.CD-12-0049.
37. Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A. 2013; 110: 17041-6. doi: 10.1073/pnas.1305170110.
38. Branzei D, Foiani M. Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol. 2010; 11: 208-19. doi: 10.1038/nrm2852.
39. Wainberg ZA, Rafii S, Ramanathan RK, Mina LA, Byers LA, Chugh R, Goldman JW, Sachdev JC, Matei DE, Wheler JJ, Henshaw JW, Zhang C, Gallant G, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. Journal of Clinical Oncology. 2014; 32. doi:.
40. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012; 2: 798-811. doi: 10.1158/2159-8290.CD-12-0112.
41. Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015; 21: 819-32. doi: 10.1158/1078-0432.CCR-14-2572.
42. Erice O, Smith MP, White R, Goicoechea I, Barriuso J, Jones C, Margison GP, Acosta JC, Wellbrock C, Arozarena I. MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. Mol Cancer Ther. 2015; 14: 1236-46. doi: 10.1158/1535-7163.MCT-14-0810.
43. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013; 19: 6322-8. doi: 10.1158/1078-0432.CCR-13-1975.
44. Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, Soule CK, Alexander B, Li A, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016; 12: 109-16. doi: 10.1038/nchembio.1986.
45. Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, Panchal SC, Wilsbacher JL, Gao W, Olson AM, Stolarik DF, Osterling DJ, Johnson EF, et al. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Mol Cancer Res. 2015; 13: 1465-77. doi: 10.1158/1541-7786.MCR-15-0191-T.
46. Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clin Cancer Res. 2016. doi: 10.1158/1078-0432.CCR-16-1040.
47. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376: 235-44. doi: 10.1016/S0140-6736(10)60892-6.
48. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol. 2011; 12: 852-61. doi: 10.1016/S1470-2045(11)70214-5.
49. Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015; 66: 455-70. doi: 10.1146/annurev-med-050913-022545.
50. O'Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015; 60: 547-60. doi: 10.1016/j. molcel.2015.10.040.
51. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483: 570-5. doi: 10.1038/nature11005.
52. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, Chinnaiyan AM. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012; 72: 1608-13. doi: 10.1158/0008-5472.CAN-11-3648.
53. Holbeck S, Chang J, Best AM, Bookout AL, Mangelsdorf DJ, Martinez ED. Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. Mol Endocrinol. 2010; 24: 1287-96. doi: 10.1210/me.2010-0040.
54. Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov. 2010; 9: 843-56. doi: 10.1038/nrd3216.
55. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339: 819-23. doi: 10.1126/science.1231143.
56. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70: 440-6. doi: 10.1158/0008-5472.CAN-09-1947.
57. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58: 621-81. doi: 10.1124/pr.58.3.10.